Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany Decision Represents Early Step in Building the Company’s Foundation Internationally MENLO PARK, Calif.—January 29, 2016—Intersect

First Page		Document Content
Date: 2016-02-02 07:14:47 Medicine Intersect ENT Propel mometasone furoate implant Sinus implant Forward-looking statement Sinusitis Otorhinolaryngology Sinus Mometasone furoate		Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany Decision Represents Early Step in Building the Company’s Foundation Internationally MENLO PARK, Calif.—January 29, 2016—Intersect Add to Reading List Source URL: propelopens.com Download Document from Source Website File Size: 136,77 KB Share Document on Facebook

	Intersect ENT Announces FDA Submission of NOVA Bioabsorbable Steroid Releasing Implant for Patients with Chronic Sinus Disease MENLO PARK, Calif.—Aug. 1, 2016—Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to DocID: 1sHld - View Document
	PROPEL® (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE: DocID: 1qyzI - View Document
	Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease Results Demonstrate Clinical Benefits of PROPEL mini in Difficult-to-Treat Patient Population MENL DocID: 1pP5m - View Document
	Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis Company Also Announces Publication of Positive Six-Month Results from RESOLVE Clinica DocID: 1okP8 - View Document
	Intersect ENT Recognized for Gender Diversity by Watermark and UC Davis Company Also Recognized in Deloitte’s 2015 Technology Fast 500 MENLO PARK, Calif., November 17, 2015 – Intersect ENT, Inc. (Nasdaq:XENT), a comp DocID: 1oeqx - View Document